Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients

Autoimmune Diseases Clinical Trial

Official title:

Frequency Assessment of Leukocyte Immunoglobulin-like Receptors A3 In Ankylosing Spondylitis And Axial Psoriatic Arthritis Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05915676
• Other study ID #: LILRA3 in AS, Axial psoriasis
• Status: Not yet recruiting
• Start date: July 1, 2023
• Est. completion date: July 30, 2024

Study information

• Verified date: June 2023
• Source: Assiut University
• Contact: Alaa Adel
• Phone: +201124098363
• Email: alaa.adel27[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

1. To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients.

2. To investigate the association of LILRA3 with Ankylosing spondylitis and Axial psoriatic arthritis disease activity and severity.

Description:

Axial spondyloarthritis (axSpA) is a complex inflammatory condition that affects the axial skeleton including the sacroiliac joints and the spine (1). It also affects peripheral joints and can be associated with extra-musculoskeletal manifestations including uveitis, psoriasis, and inflammatory bowel disease (1).

Axial spondyloarthritis include ankylosing spondylitis (AS), certain forms of psoriatic arthritis (PsA), reactive arthritis with axial involvement, and arthritis associated with inflammatory bowel disease (2).

The diagnosis of axSpA remains very challenging with years of delays attributed to several different factors. There is also a strong need to identify new serological biomarkers that can aid clinicians for diagnosis of axSpA.

Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: July 30, 2024
• Est. primary completion date: June 1, 2024
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:Adult AS and axPsA patients <18 years Who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) criteria for axSpA.

-

Exclusion Criteria:1-patients less than 18 years old

2-Individuals with other autoimmune diseases

-

Related Conditions & MeSH terms

• Autoimmune Diseases
• Spondylitis
• Spondylitis, Ankylosing

Intervention

Diagnostic Test:
• Leukocyte Immunoglobulin-like receptors A3
Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (4)

Norman PJ, Carey BS, Stephens HAF, Vaughan RW. DNA sequence variation and molecular genotyping of natural killer leukocyte immunoglobulin-like receptor, LILRA3. Immunogenetics. 2003 Jun;55(3):165-171. doi: 10.1007/s00251-003-0561-1. Epub 2003 May 16. — View Citation

Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013 Feb;5(1):45-54. doi: 10.1177/1759720X12468658. — View Citation

Ryu M, Chen Y, Qi J, Liu J, Fan Z, Nam G, Shi Y, Cheng H, Gao GF. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence. PLoS One. 2011 Apr 29;6(4):e19245. doi: 10.1371/journal.pone.0019245. — View Citation

Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018 Mar;30(2):137-143. doi: 10.1097/BOR.0000000000000475. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LILRA3 in AS and Axial psoriatic arthritis patients.	To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients.	Baseline
Secondary	Assosciation of LILRA3 with disease severity	To investigate the association of LILRA3 with Ankylosing spondylitis and Axial psoriatic arthritis disease activity and severity.	Baseline